Home/IHP Therapeutics/Gabriel Njikang
GN

Gabriel Njikang

CMC

IHP Therapeutics

Therapeutic Areas

IHP Therapeutics Pipeline

DrugIndicationPhase
IHP-102Acute vaso-occlusive crisis in sickle cell diseasePre-clinical